PTC Therapeutics Inc [PTCT] stock is trading at $52.13, up 0.04%. An important factor to consider is whether the stock is rising or falling in short-term value. The PTCT shares have gain 16.52% over the last week, with a monthly amount glided 6.06%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
PTC Therapeutics Inc [NASDAQ: PTCT] stock has seen the most recent analyst activity on June 17, 2025, when Truist initiated its Buy rating and assigned the stock a price target of $80. Previously, BofA Securities upgraded its rating to Buy on May 09, 2025, and kept the price target unchanged to $68. On May 07, 2025, upgrade upgraded it’s rating to Neutral but maintained its price target of $40 on the stock. BofA Securities upgraded its rating to a Neutral and increased its price target to $55 on March 11, 2025. Scotiabank initiated its recommendation with a Sector Perform and recommended $55 as its price target on March 07, 2025. Morgan Stanley upgraded its rating to Overweight for this stock on December 13, 2024, and upped its price target to $67. In a note dated December 03, 2024, RBC Capital Mkts upgraded an Outperform rating on this stock and boosted its target price from $39 to $63.
PTC Therapeutics Inc [PTCT] stock has fluctuated between $29.01 and $58.38 over the past year. Currently, Wall Street analysts expect the stock to reach $66 within the next 12 months. PTC Therapeutics Inc [NASDAQ: PTCT] shares were valued at $52.13 at the most recent close of the market. An investor can expect a potential return of 26.61% based on the average PTCT price forecast.
Analyzing the PTCT fundamentals
PTC Therapeutics Inc [NASDAQ:PTCT] reported sales of 1.77B for the trailing twelve months, which represents a growth of 459.73%. Gross Profit Margin for this corporation currently stands at 0.97% with Operating Profit Margin at 0.41%, Pretax Profit Margin comes in at 0.37%, and Net Profit Margin reading is 0.34%. To continue investigating profitability, this company’s Return on Assets is posted at 0.22, Equity is -0.72 and Total Capital is 0.35. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-2.1.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 51.07 points at the first support level, and at 50.00 for the second support level. However, for the 1st resistance point, the stock is sitting at 52.80, and for the 2nd resistance point, it is at 53.47.
Ratios To Look Out For
For context, PTC Therapeutics Inc’s Current Ratio is 3.89. On the other hand, the Quick Ratio is 3.85, and the Cash Ratio is 2.49. Considering the valuation of this stock, the price to sales ratio is 2.33 and price to earnings (TTM) ratio is 8.01.
Transactions by insiders
Recent insider trading involved Gravier Pierre, CHIEF FINANCIAL OFFICER, that happened on Jul 15 ’25 when 2516.0 shares were sold. Officer, Gravier Pierre completed a deal on Jul 15 ’25 to buy 2516.0 shares. Meanwhile, EXEC. VP AND CLO Boulding Mark Elliott sold 1929.0 shares on May 15 ’25.
